For patients with no known actionable genomic tumor driver mutations or molecular biomarkers, ICIs, specifically PD-1/PD-L1 inhibitor monotherapy or in combination with PBC (PD-1/PD-L1 inhibitor combination), are recommended. This evidence concerns the gene CD274 and neoplasm.